On optimal temozolomide scheduling for slowly growing glioblastomas

BACKGROUND: Temozolomide (TMZ) is an oral alkylating agent active against gliomas with a favorable toxicity profile. It is part of the standard of care in the management of glioblastoma (GBM), and is commonly used in low-grade gliomas (LGG). In-silico mathematical models can potentially be used to p...

Descripción completa

Detalles Bibliográficos
Autores principales: Segura-Collar, Berta, Jiménez-Sánchez, Juan, Gargini, Ricardo, Dragoj, Miodrag, Sepúlveda-Sánchez, Juan M, Pešić, Milica, Ramírez, María A, Ayala-Hernández, Luis E, Sánchez-Gómez, Pilar, Pérez-García, Víctor M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616068/
https://www.ncbi.nlm.nih.gov/pubmed/36325374
http://dx.doi.org/10.1093/noajnl/vdac155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616068/
https://www.ncbi.nlm.nih.gov/pubmed/36325374
http://dx.doi.org/10.1093/noajnl/vdac155

Ejemplares similares